

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Weinhoff Gregory M</u> (Last) (First) (Middle) <u>C/O CHL MEDICAL PARTNERS</u> <u>1055 WASHINGTON BLVD.</u> (Street) <u>STAMFORD CT 06901</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS INC [FOLD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/05/2007</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/05/2007		C		1,975,223	A	(1)	2,108,555	I	By Partnership ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Convertible Preferred Stock	(1)	06/05/2007		C			83,278	04/15/2002	(1)	Common Stock	83,278	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series A Convertible Preferred Stock	(1)	06/05/2007		C			5,611	04/15/2002	(1)	Common Stock	5,611	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series B Convertible Preferred Stock	(1)	06/05/2007		C			734,803	05/04/2004	(1)	Common Stock	734,803	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series B Convertible Preferred Stock	(1)	06/05/2007		C			49,509	05/04/2004	(1)	Common Stock	49,509	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series B Convertible Preferred Stock	(1)	06/05/2007		C			11,182	04/18/2006	(1)	Common Stock	11,182	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series B Convertible Preferred Stock	(1)	06/05/2007		C			753	04/18/2006	(1)	Common Stock	753	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C			247,850	08/16/2005	(1)	Common Stock	247,850	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C			16,669	08/16/2005	(1)	Common Stock	16,699	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series C Convertible Preferred Stock	(1)	06/05/2007		C			247,850	04/17/2006	(1)	Common Stock	247,850	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Convertible Preferred Stock	(1)	06/05/2007		C			16,669	04/17/2006	(1)	Common Stock	16,699	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C			96,233	09/13/2006	(1)	Common Stock	96,233	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C			6,484	09/13/2006	(1)	Common Stock	6,484	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C			96,223	03/09/2007	(1)	Common Stock	96,233	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series D Convertible Preferred Stock	(1)	06/05/2007		C			6,484	03/09/2007	(1)	Common Stock	6,484	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾
Series A Convertible Preferred Stock	(1)	06/05/2007		C			333,111	07/15/2002	(1)	Common Stock	333,111	\$0	0	I	By CHL Medical Partners II, L.P. ⁽²⁾
Series A Convertible Preferred Stock	(1)	06/05/2007		C			22,444	07/15/2002	(1)	Common Stock	22,444	\$0	0	I	By CHL Medical Partner II Side Fund, L.P. ⁽³⁾

Explanation of Responses:

- Each of the Series A Convertible Preferred Stock, the Series B Convertible Preferred Stock, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one-for-one basis upon the closing of Amicus Therapeutics, Inc.'s initial public offering on June 5, 2007
- The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.
- The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.
- Consists of 1,975,456 shares held by CHL Medical Partner II, L.P. and 133,099 shares held by CHL Medical Partners II Side Fund, L.P. The reporting person is a partner of Collinson, Howe & Lennox II, LLC, which is the general partner of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. Voting and investment power over these shares is exercised by Collinson, Howe & Lennox II, LLC in its role as general partner and investment advisor of CHL Medical Partners II, L.P. and CHL Medical Partners II Side Fund, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 or for any other purpose.

/s/ Gregory M. Weinhoff

06/06/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.